Browse FSHR

Summary
SymbolFSHR
Namefollicle stimulating hormone receptor
Aliases FSHRO; LGR1; ODG1; FSHR1O; FSH receptor; follitropin receptor; FSH-R; Follicle-stimulating hormone receptor
Chromosomal Location2p21-p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF00001 7 transmembrane receptor (rhodopsin family)
PF12369 Gonadotropin hormone receptor transmembrane region
PF13306 Leucine rich repeats (6 copies)
PF01462 Leucine rich repeat N-terminal domain
Function

Receptor for follicle-stimulating hormone or follitropin (PubMed:11847099, PubMed:24058690). The activity of this receptor is mediated by G proteins which activate adenylate cyclase (PubMed:11847099). Induces cAMP production through the activation of PI3K-AKT and SRC-ERK1/2 signaling pathways (PubMed:24058690).

> Gene Ontology
 
Biological Process GO:0001541 ovarian follicle development
GO:0001545 primary ovarian follicle growth
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007189 adenylate cyclase-activating G-protein coupled receptor signaling pathway
GO:0007190 activation of adenylate cyclase activity
GO:0007283 spermatogenesis
GO:0007292 female gamete generation
GO:0007548 sex differentiation
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0008585 female gonad development
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0009755 hormone-mediated signaling pathway
GO:0010737 protein kinase A signaling
GO:0010738 regulation of protein kinase A signaling
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0022602 ovulation cycle process
GO:0030099 myeloid cell differentiation
GO:0030316 osteoclast differentiation
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030804 positive regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030810 positive regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030819 positive regulation of cAMP biosynthetic process
GO:0031279 regulation of cyclase activity
GO:0031281 positive regulation of cyclase activity
GO:0042698 ovulation cycle
GO:0042699 follicle-stimulating hormone signaling pathway
GO:0043410 positive regulation of MAPK cascade
GO:0045137 development of primary sexual characteristics
GO:0045637 regulation of myeloid cell differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045761 regulation of adenylate cyclase activity
GO:0045762 positive regulation of adenylate cyclase activity
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046545 development of primary female sexual characteristics
GO:0046546 development of primary male sexual characteristics
GO:0046660 female sex differentiation
GO:0046661 male sex differentiation
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048232 male gamete generation
GO:0048511 rhythmic process
GO:0048608 reproductive structure development
GO:0051339 regulation of lyase activity
GO:0051349 positive regulation of lyase activity
GO:0052652 cyclic purine nucleotide metabolic process
GO:0061458 reproductive system development
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0072522 purine-containing compound biosynthetic process
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900373 positive regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1902105 regulation of leukocyte differentiation
GO:1903706 regulation of hemopoiesis
Molecular Function GO:0001653 peptide receptor activity
GO:0004963 follicle-stimulating hormone receptor activity
GO:0008528 G-protein coupled peptide receptor activity
GO:0016500 protein-hormone receptor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04024 cAMP signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
hsa04913 Ovarian steroidogenesis
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418555: G alpha (s) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375281: Hormone ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolFSHR
Namefollicle stimulating hormone receptor
Aliases FSHRO; LGR1; ODG1; FSHR1O; FSH receptor; follitropin receptor; FSH-R; Follicle-stimulating hormone receptor
Chromosomal Location2p21-p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FSHR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FSHR and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26112923Ovarian CarcinomaInhibit immunity (T cell function)Receptor ligand-based anti-FSHR immunoreceptors were constructed that contained small binding fragments from the ligand for FSHR, FSH, fused to T-cell transmembrane and T-cell signaling domains. Human T cells transduced to express anti-FSHR immunoreceptors were specifically immunoreactive against FSHR-expressing human and mouse ovarian cancer cell lines in an MHC-nonrestricted manner and mediated effective lysis of FHSR-expressing tumor cells, but not FSHR-deficient targets, in vitro.
27435394Ovarian CarcinomaPromote immunity (T cell function); essential for immunotherapyFSHR is expressed in gynecologic malignancies of different histologic types but not in nonovarian healthy tissues. T cells redirected against FSHR+ tumor cells with full-length FSH represent a promising therapeutic alternative against a broad range of ovarian malignancies, with negligible toxicity even in the presence of cognate targets in tumor-free ovaries.
Summary
SymbolFSHR
Namefollicle stimulating hormone receptor
Aliases FSHRO; LGR1; ODG1; FSHR1O; FSH receptor; follitropin receptor; FSH-R; Follicle-stimulating hormone receptor
Chromosomal Location2p21-p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FSHR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFSHR
Namefollicle stimulating hormone receptor
Aliases FSHRO; LGR1; ODG1; FSHR1O; FSH receptor; follitropin receptor; FSH-R; Follicle-stimulating hormone receptor
Chromosomal Location2p21-p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FSHR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.8580.265
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0160.461
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6770.617
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2980.144
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FSHR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117190190.113
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFSHR
Namefollicle stimulating hormone receptor
Aliases FSHRO; LGR1; ODG1; FSHR1O; FSH receptor; follitropin receptor; FSH-R; Follicle-stimulating hormone receptor
Chromosomal Location2p21-p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FSHR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFSHR
Namefollicle stimulating hormone receptor
Aliases FSHRO; LGR1; ODG1; FSHR1O; FSH receptor; follitropin receptor; FSH-R; Follicle-stimulating hormone receptor
Chromosomal Location2p21-p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FSHR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FSHR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFSHR
Namefollicle stimulating hormone receptor
Aliases FSHRO; LGR1; ODG1; FSHR1O; FSH receptor; follitropin receptor; FSH-R; Follicle-stimulating hormone receptor
Chromosomal Location2p21-p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FSHR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFSHR
Namefollicle stimulating hormone receptor
Aliases FSHRO; LGR1; ODG1; FSHR1O; FSH receptor; follitropin receptor; FSH-R; Follicle-stimulating hormone receptor
Chromosomal Location2p21-p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FSHR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFSHR
Namefollicle stimulating hormone receptor
Aliases FSHRO; LGR1; ODG1; FSHR1O; FSH receptor; follitropin receptor; FSH-R; Follicle-stimulating hormone receptor
Chromosomal Location2p21-p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FSHR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFSHR
Namefollicle stimulating hormone receptor
Aliases FSHRO; LGR1; ODG1; FSHR1O; FSH receptor; follitropin receptor; FSH-R; Follicle-stimulating hormone receptor
Chromosomal Location2p21-p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FSHR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FSHR.
ID Name Drug Type Targets #Targets
DB00032MenotropinsBiotechFSHR, LHCGR2
DB00066FollitropinBiotechFSHR1
DB00094UrofollitropinBiotechFSHR1
DB00097Choriogonadotropin alfaBiotechFSHR, LHCGR2
DB04786SuraminSmall MoleculeF2, FSHR, P2RY2, PLA2G2A, RYR1, SIRT56